Norgine Gains Australia Approval for PEDMARQSI®
AMSTERDAM, The Netherlands – May 6, 2026 Norgine has announced that the Australian Therapeutic Goods Administration (TGA) has granted...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Bispecific Antibody cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
AMSTERDAM, The Netherlands – May 6, 2026 Norgine has announced that the Australian Therapeutic Goods Administration (TGA) has granted...
